Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2006

View Archived Issues

Chemopreventative potential of the rexinoid bexarotene

Preclinical and clinical studies examine ocular effects of bevacizumab

Preclinical update on MLN-8054

Denileukin-mediated depletion of Tregs: an important anticancer strategy / News in Context

SUVN-501 elevates hippocampal levels of acetylcholine as a potential procognitive treatment

AdipoGenix and Unigen to develop plant-based therapeutics that target fat

Tigris studies A-007 in high-grade CIN

Isis transaction to fund drug development programs

Novartis seeks approvals for Glivec in rare cancers

FX-06 for reperfusion injury safe and well tolerated in phase I study

Affiris closes EUR 8.5 million financing round

Pfizer to acquire Rinat Neuroscience

Cardiome Pharma recaps Q4 highlights

TRO-19622: clinical candidate for motor neuron disease

Preclinical proof-of-concept for Myodur in DMD

European approval for Adartrel in RLS

Novel anti-HCV drugs reported by Merck and Istituto di Ricerche di Biologia Molecolare P. Angeletti

Recent Altana patent divulges new PDE2 inhibitors for septic shock

Recent patents describe new agents for anxiety, depression, sleep disorders, etc.

Heterotrimeric G-protein complex inhibitor BIM-46187 presented at AACR meeting

Update of Synta Pharmaceutical's STA-5326 mesylate under clinical investigation

Bone-targeted rapamycin analogue with both antitumor and antiosteolytic effects

Dasatinib shows clinical benefit in CML patients resistant to imatinib

Recombinant immunocytotoxic protein for ovarian cancer shows good preclinical profile

Preclinical data on a human conjugated monoclonal antibody developed by CuraGen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...